Post-COVID syndrome in the neurological practice

Close metadata

Recommended articles:

Promising approaches to the pathogenetic therapy of amyotrophic lateral sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):13-21

Long-term follow-up of adult patients with serial and status course of epileptic seizures. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):63-68

Results of a pilot study of the structure and evaluation of the therapy for chronic sleep disorders in comorbid patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):118-126

Prevalence of cognitive impairment in older adults in the Russian Federation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):5-11

Cognitive impairment in multiple system atrophy — exclusion criteria or an integral part of the clinical picture?. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):86-91

Efficacy and safety of choline alfoscerate in the preventive therapy of dementia in elderly patients with Mild Cognitive Impairment: a three-year prospective comparative study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):92-99

Clinical and morphological assessment of patients with adenomyosis: own data. Russian Journal of Human Reproduction. 2024;(2):130-135

Efficacy and safety of a new selective oral factor Xa inhibitor amidine hydrochloride for the prevention of thromboembolic events in hospitalized patients with COVID-19. Results of a multicenter, prospective, randomized, controlled study. Journal of Venous Disorders. 2024;(2):154-162

Structural-functional status of cardiovascular and respiratory systems, psychoemotional disorders in patients with COVID-19 at the time of hospital discharge. Russian Journal of Preventive Medicine. 2024;(5):60-68

Use of systemic steroids in hospitalized patients with COVID-19. Russian Journal of Preventive Medicine. 2024;(5):75-80

Postcovid syndrome (PCS) is a complex multifactorial clinical condition that is a frequent complication of COVID-19. The development of PCS does not depend on the severity of the initial infectious disease, it has a pronounced effect on the quality of life and is characterized by a tendency to a protracted course. In the context of the ongoing COVID-19 pandemic, the emergence of new variants of the SARS-CoV-2 virus, it is important to develop common approaches to the diagnosis and management of patients suffering from this medical condition. The review presents current data on the epidemiology, pathogenesis, clinical presentation, and diagnosis of the PCS. The approaches to therapy of PCS are discussed, as well as the role of Cortexin, taking into account both theoretical and accumulated clinical data.

Keywords:

COVID-19

post-COVID syndrome

prevalence

pathogenesis

management

Cortexin

Authors:

Cherdak M.A.

Pirogov Russian National Research Medical University

Scopus AuthorID: 57201377824
ORCID: 0000-0002-9054-0881

Mkhitaryan E.A.

Pirogov Russian National Research Medical University;
Russian Clinical and Research Center of Gerontology Pirogov — Russian National Research Medical University

SPIN RSCI: 6822-2682
Scopus AuthorID: 24449712100
ORCID: 0000-0003-2597-981X

Received:

04.04.2023

Accepted:

11.04.2023

List of references:

Mokhtari T, Hassani F, Ghaffari N, et al. COVID-19 and multiorgan failure: A narrative review on potential mechanisms. J Mol Histol. 2020 Dec;51(6):613-628. https://doi.org/10.1007/s10735-020-09915-3
Asfandiyarova NS. Post-COVID-19 syndrome. Clinical Medicine (Russian Journal). 2021;99(7-8):429-435. (In Russ.). https://doi.org/10.30629/0023-2149-2021-99-7-8-429-435
Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9(2):129. https://doi.org/10.1016/S2213-2600(21)00031-X
Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615. https://doi.org/10.1038/s41591-021-01283-z
Post-COVID Conditions: Information for Healthcare Providers. Accessed: 20.03.2023. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
Post COVID-19 condition. Accessed: 20.03.2023. Available at: https://www.who.int/teams/health-care-readiness/post-covid-19-condition
Chen C, Haupert SR, Zimmermann L, et al. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022;226(9):1593-1607. https://doi.org/10.1093/infdis/jiac136
Pazukhina E, Andreeva M, Spiridonova E, et al. Sechenov StopCOVID Research Team. Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID). BMC Med. 2022;20(1):244. https://doi.org/10.1186/s12916-022-02448-4
Prevalence of post COVID-19 condition symptoms: a systematic review and meta-analysis of cohort study data, stratified by recruitment setting. Technical report of European Centre for Diease Prevention and Control. Accessed: 20.03.2023. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/Prevalence-post-COVID-19-condition-symptoms.pdf
Montenegro P, Moral I, Puy A, et al. Prevalence of Post COVID-19 Condition in Primary Care: A Cross Sectional Study. Int J Environ Res Public Health. 2022;19(3):1836. https://doi.org/10.3390/ijerph19031836
Putilina MV, Mutovina ZYu, Kurushina OV, et al. Determination of the prevalence of postcovid syndrome and assessment of the effectiveness of the drug Cortexin in the treatment of neurological disorders in patients with postcovid syndrome. Results of the multicenter clinical and epidemiological observational program CORTEX. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2022;122(1):84-90. (In Russ.). https://doi.org/10.17116/jnevro202212201184
Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1):16144. https://doi.org/10.1038/s41598-021-95565-8
Petrova LV, Kostenko EV, Eneeva MA. Asthenia and Post-COVID Syndrome: Pathogenesis, Clinical Presentations, Diagnosis, and Medical Rehabilitation. Doctor Ru. 2021;20(9):36-42. (In Russ.). https://doi.org/10.31550/1727-2378-2021-20-9-36-42
Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021 Aug; 38:101019. https://doi.org/10.1016/j.eclinm.2021.101019
Ceban F, Ling S, Lui LMW, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav Immun. 2021;101:93-135. https://doi.org/10.1016/J.BBI.2021.12.020
Morgul E, Bener A, Atak M, et al. COVID-19 pandemic and psychological fatigue in Turkey. Int J Soc Psychiatry. 2021 Mar;67(2):128-135. https://doi.org/10.1177/0020764020941889
Salari N, Khodayari Y, Hosseinian-Far A, et al. Global prevalence of chronic fatigue syndrome among long COVID-19 patients: A systematic review and meta-analysis. Biopsychosoc Med. 2022;16(1):21. https://doi.org/10.1186/s13030-022-00250-5
Gaber T. Assessment and management of post-COVID fatigue. Prog Neurol Psychiatry. 2021;25:36-39. https://doi.org/10.1002/pnp.698
Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome a case-controlled study. BMC Neurol. 2011;11:37-41. https://doi.org/10.1186/1471-2377-11-37
Hellmuth J, Barnett TA, Asken BM, et al. Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. J Neurovirol. 2021;27:191. https://doi.org/10.1007/S13365-021-00954-4
Salamanna F, Veronesi F, Martini L, et al. Post-COVID-19 Syndrome: The Persistent Symptoms at the Post-viral Stage of the Disease. A Systematic Review of the Current Data. Front Med (Lausanne). 2021 May 4;8:653516. https://doi.org/10.3389/fmed.2021.653516
Afroze F, Arafat SM, Ahmed CM, et al. Features and risk factors of post-COVID-19 syndrome: findings from a longitudinal study in Bangladesh. Lancet Reg Health Southeast Asia. 2022 Dec 23:100134. https://doi.org/10.1016/j.lansea.2022.100134
Batiha GE, Al-Kuraishy HM, Al-Gareeb AI, Welson NN. Pathophysiology of Post-COVID syndromes: a new perspective. Virol J. 2022;19(1):158. https://doi.org/10.1186/s12985-022-01891-2
Majolo F, Silva GL, Vieira L, et al. Neuropsychiatric disorders and COVID-19: what we know so far. Pharmaceuticals. 2021;14(9):933. https://doi.org/10.3390/ph14090933
Kumar D, Jahan S, Khan A, et al. Neurological manifestation of SARS-CoV-2 induced inflammation and possible therapeutic strategies against COVID-19. Mol Neurobiol. 2021;58(7):3417-3434. https://doi.org/10.1007/s12035-021-02318-9
Chen R, Wang K, Yu J, et al. The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 in the Human and Mouse Brains. Front Neurol. 2021 Jan 20;11:573095. https://doi.org/10.3389/fneur.2020.573095
Serebrovska ZO, Chong EY, Serebrovska TV. Hypoxia, HIF-1α, and COVID-19: from pathogenic factors to therapeutic targets. Acta Pharmacol Sin. 2020;41:1539-1546. https://doi.org/10.1038/s41401-020-00554-8
Pavli A, Theodoridou M, Maltezou HC. Post-COVID syndrome: Incidence, clinical spectrum, and challenges for primary healthcare professionals. Arch Med Res. 2021:S0188-4409(21)00081-3. https://doi.org/10.1016/j.arcmed.2021.03.010
Petrella C, Nenna R, Petrarca L, et al. Serum NGF and BDNF in Long-COVID-19 Adolescents: A Pilot Study. Diagnostics (Basel). 2022 May 7;12(5):1162. https://doi.org/10.3390/diagnostics12051162
Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020 Nov 26;9(1):42. https://doi.org/10.1186/s40035-020-00221-2
Versace V, Sebastianelli L, Ferrazzoli D, et al. Intracortical GABAergic dysfunction in patients with fatigue and dysexecutive syndrome after COVID-19. Clin Neurophysiol. 2021;132:1138. https://doi.org/10.1016/J.CLINPH.2021.03.001
Putilina MV. Asthenic disorders as a manifestation of chronic fatigue syndrome. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(8):119-124. (In Russ.). https://doi.org/10.17116/jnevro2021121081119
Tkacheva ON, Kotovskaya YuV, Runikhina NK, et al. Clinical guidelines on frailty. Russian Journal of Geriatric Medicine. 2020;(1):11-46. (In Russ.). https://doi.org/10.37586/2686-8636-1-2020-11-46
Khasanova DR, Zhitkova YuV, Vaskaeva GR. Post-covid syndrome: a review of pathophysiology, neuropsychiatric manifestations and treatment perspectives. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(3):93-98. (In Russ.). https://doi.org/10.14412/2074-2711-2021-3-93-98
Yakovlev AA, Gulyaeva NV. Molecular partners of cortexin in the brain. Neurochemistry. 2017;33:1:91-96. (In Russ.). https://doi.org/10.1134/S1819712416040164
Nesterenko AN, Onufriev MV, Gulyaeva NV. Effect of the drug Cortexin on free radical oxidation and inflammatory processes in rats with normal and accelerated aging. Neurochemistry. 2018;2(35):187-198. (In Russ.). https://doi.org/10.7868/S1027813318020127
Kurkin DV, Bakulin DA, Morkovin EI, et al. Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats. PLoS One. 2021 Jul 14;16(7):e0254493. https://doi.org/10.1371/journal.pone.0254493
Ludewig P, Winneberger J, Magnus T. The cerebral endothelial cell as a key regulator of inflammatory processes in sterile inflammation. J Neuroimmunol. 2019;326:38-44. https://doi.org/10.1016/j.jneuroim.2018.10.012

Close metadata